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Human serum contains 2 isoforms of type-5 tartrate-resistant acid phosphatase (TRACP): 5a and 5b. TRACP-5b is osteoclastic. Our goal was to determine if serum TRACP-5a could originate from inflammatory macrophages (MΦ)
Tartrate-resistant acid phosphatase (TRACP), also known as type-5 acid phosphatase and purple acid phosphatase, is an iron-containing glycoprotein expressed primarily by cells of monocyte-macrophage lineage. [1] [2] [3] Human TRACP exists as 2 distinct isoforms, 5a and 5b. TRACP-5a is an intact polypeptide and has sialic acid in its N-linked oligosaccharide(s). TRACP-5b is proteolytically processed, yielding a disulfidebonded heterodimer, and has no detectable sialic acid. TRACP-5a has a pH optimum of 5.2 and a specific activity of 100 to 200 U/mg. TRACP-5b has a higher pH optimum of 5.8 and a higher specific activity of 1,000 to 2,000 U/mg. TRACP-5a migrates more slowly than TRACP-5b in acidic, nondenaturing polyacrylamide gel electrophoresis. 4, 5 Human serum contains TRACP-5a and TRACP-5b. By using an immunoassay specific for TRACP-5b, it is possible to show that serum TRACP-5b activity correlates most closely with bone resorption markers and osteoclast number. 6, 7 Serum TRACP-5b activity is a promising new marker with clinical relevance in diseases with increased bone resorption and destruction. [8] [9] [10] [11] The origin and relevance of serum TRACP-5a is less certain because assays specific for isoform 5a have not been available until now. Our early work with the TRACP immunoassay showed that TRACP protein was increased in about 30% of serum samples from patients with rheumatoid arthritis (RA) and was probably due to increased isoform 5a. Subsequently, Janckila et al 12 developed monoclonal antibody (mab)220 against recombinant human TRACP expressed in Chinese hamster ovary cells. 13 Mab220 reacts with a protease sensitive epitope within the so-called regulatory loop peptide. This epitope is destroyed when TRACP is processed in vitro or in vivo to yield isoform 5b. Therefore, mab220 is specific for serum TRACP-5a, but will also react with unprocessed precursor enzyme protein. By using this antibody in an immunoassay, Chao et al 14 confirmed that one third of patients with RA have increased serum TRACP-5a protein. Neither the levels of total TRACP protein or isoform 5a protein or isoform 5a activity are correlated to markers of bone resorption. Furthermore, TRACP-5a levels do not respond to antiresorptive therapy. 6 We hypothesize that the elevated TRACP-5a in RA is derived from inflammatory macrophages (MΦ) and that this isoform could be a marker of disease activity in a variety of other chronic inflammatory diseases.
Previously, Yaziji et al 2 used mab9C5 that reacts with TRACP-5a and TRACP-5b to conduct an immunohistochemical survey of normal and diseased human tissues for expression of TRACP. They established that, in addition to the hairy cells of hairy cell leukemia, the only cells to express TRACP were osteoclasts and some, but not all, MΦ. The MΦ that were TRACP+ were especially associated with inflammatory pathologies or in areas of chronic antigenic stimulation such as alveolar MΦ of lung and MΦ in the lamina propria of gastrointestinal tissues.
The goals of the present study were to use mab220 as an immunohistochemical marker to lend further support to our hypothesis that serum TRACP-5a is derived from inflammatory MΦ and to disclose other potential sources for serum TRACP-5a. In addition, we sought to determine whether mab220 could discriminate activated or inflammatory MΦ from resident tissue histiocytes. Finally, from a purely practical viewpoint, we wanted to determine whether mab220 was a more sensitive or specific immunohistochemical marker than mab9C5 for TRACP-expressing cells in formalin-fixed, paraffin-embedded tissue samples.
Materials and Methods
Tissue Specimens
Tissue sections were cut from a total of 246 formalinfixed, paraffin-embedded archived surgical specimens dating from 1986 to 2005 ❚Table 1❚. Of these sections, 209 dating from 1986 to 1995 were previously stained for TRACP with mab9C5 and results reported earlier. 2 An additional 37 specimens were retrieved from archival material from 2004 and 2005. Of these specimens, 184 were available for additional staining for TRACP with mab220. In addition, 158 were stained for CD68 and 45 for lysozyme as additional markers of MΦ. The pathologic processes within these tissues are categorized in ❚Table 2❚. The institutional review boards of the Veterans Affairs Medical Center and the University of Louisville, Louisville, KY, approved this study with full waiver of authorization.
Immunohistochemical Analysis
Sections were deparaffinized, hydrated, and subjected to heat-induced epitope retrieval by incubation overnight at 72°C in a commercial solution of EDTA according to the manufacturer's protocol (Zymed Laboratories, South San Francisco, CA). Sections were then incubated for 1 hour in primary anti-TRACP antibodies. Mab9C5 was tested at dilutions from 1:100 to 1:2,000 and used at an optimized dilution of 1:500 of ascites. Mab220 was tested at dilutions from 1:500 to 1:5,000 and, having about 10-fold more antibody IgG, was used at an optimized dilution of 1:5,000 of ascites. In some cases, anti-CD68 and antilysozyme were used as markers to identify MΦ. Control stains were done with antibody dilution buffer or with control mouse ascites at 1:500. All stains were performed using an automated robotic stainer (Autostainer, DAKO, Carpinteria, CA) and a commercial peroxidase-conjugated streptavidin-biotin detection system (LSAB2, DAKO).
In some problematic tissue samples of the gastrointestinal tract, genitourinary tract, kidney, skin, and thyroid, unexpected weak staining for TRACP and nonspecific staining of control samples were present in some epithelial cells and renal tubules. These and other representative specimens of the same tissue origin were subsequently restained directly comparing the LSAB2 detection system with a biotin-free system (EnVision, DAKO). For these follow-up studies, IgGs were purified from mab9C5, mab220, and control ascites and adjusted to 1 mg/mL. Antibodies were then tested at dilutions from 1:200 to 1:2,000 and used at their optimum for each system: 1:1,000 for LSAB2 and 1:500 for EnVision. Results showed that the nonspecific staining in epithelia and tubules were due to nonspecific binding of IgG or to the presence of endogenous biotin.
Results
General Findings
Cells of monocyte-MΦ lineage were stained to variable degrees with all 4 marker antibodies. Overall, CD68 (monocyte lysosomes) and mab220 (TRACP-5a and precursor enzyme) staining were the strongest, whereas mab9C5 staining for total TRACP was the weakest. All cells of monocyte lineage were stained for CD68, including osteoclasts, MΦ, dendritic cells (DCs), and Kupffer cells. Lysozyme was present in all monocytic cells except osteoclasts, but also stained myeloid cells in bone marrow and polymorphonuclear leukocytes in areas of acute inflammation. TRACP staining was strongest in MΦ of chronic and granulomatous inflammatory tissues and areas that normally undergo strong antigenic stimulation such as alveolar MΦ of lung and lamina propria of gastrointestinal tissues. Other pathologies containing MΦ with strong TRACP expression included some high-grade malignant tumors undergoing rapid cell turnover and areas adjacent to abscesses and in rheumatoid nodules. In such cells, mab220 staining was always stronger than mab9C5 staining. TRACP staining with either antibody was weak to negative in MΦ associated with removal of apoptotic or senescent cells such as tingible body MΦ of lymphoid germinal centers and in the red pulp MΦ of normal spleen. Hyperplastic sinus histiocytes in lymph node were also weak or negative for TRACP staining. More detailed descriptions of specific staining patterns and other noteworthy results follow. 
Hematopoietic System
Expression of CD68 was used as the defining marker for cells of monocyte-MΦ lineage. TRACP expression by CD68+ cells was variable in bone marrow, spleen, and lymph node, with mab220 always giving a stronger reaction in more cells than mab9C5. In the bone marrow, lysozyme was expressed by MΦ and granulocytes in various stages of maturation. In bone marrow and splenic red pulp, most MΦ were strongly positive for CD68 ❚Image 1A❚ and ❚Image 1C❚ and lysozyme but weak or negative for TRACP ❚Image 1B❚ and ❚Image 1D❚. In contrast, some MΦ within the splenic white pulp were strongly TRACP+. Staining intensity with mab220 was always stronger than mab9C5. The marginal zone (MZ) lymphocytes of 3 normal spleens ❚Image 2❚ and a case of splenic MZ lymphoma were weakly to moderately positive for TRACP expression. In lymph nodes, the sinus histiocytes were strongly positive for CD68 and lysozyme but weakly positive for TRACP. The MΦ within the germinal centers of spleen and lymph nodes were variable in TRACP intensity. The tingible body MΦ were characteristically weak to negative for TRACP ❚Image 3❚. Follow-up staining with CD21 revealed an intense network throughout the germinal centers, a much different staining pattern than TRACP. Therefore, TRACP positivity was not associated with follicular DCs. On the other hand, mab220 and anti-CD21 resulted in the same staining pattern within the MZ. 
Gastrointestinal System
In normal tissues throughout the gastrointestinal tract, MΦ were positive for CD68, lysozyme, and TRACP. TRACP expression was weak or absent in MΦ within the submucosa but was strongly expressed by MΦ in the lamina propria of the small and large bowel ❚Image 4A❚. Two specimens of stomach and 2 of small intestine were stained for CD117, which revealed that many of the strongly TRACP+ cells in the mucosa and submucosa were mast cells. In various gastrointestinal tissues, including stomach, small intestine, and colon, there were variable numbers of epithelial cells that stained strongly with mab9C5 ❚Image 4B❚ but were universally negative with mab220 and negative for CD68 expression. These cells were identified as neuroendocrine cells by virtue of chromogranin staining ❚Image 4C❚. Many tissues of the gastrointestinal tract showed variable degrees of staining in epithelial cells using anti-TRACP ascites or control ascites or buffer. Repeated stains using optimized concentrations of purified IgGs with a biotin-free detection system revealed epithelial cells to be TRACP-. The variable staining with LSAB2 and diluted ascites was probably due to nonspecific protein binding and endogenous tissue biotin.
Genitourinary System
In normal tissue samples, MΦ were positive for CD68, lysozyme, and sometimes TRACP when mab220 was used but were mostly negative for TRACP when mab9C5 was used. In inflammatory tissues, increased numbers of MΦ were strongly positive for TRACP with mab220 or mab9C5. As in gastrointestinal tissues, the epithelia of some genitourinary tract tissues were sometimes nonspecifically positive for TRACP but negative for CD68 and lysozyme. Proximal tubular cells in some kidney tissues were variably positive for TRACP with mab220 or mab9C5 and strongly positive for lysozyme. Repeated stains using a biotin-free detection system and optimized amounts of purified IgGs revealed that proximal tubular cells indeed were positive for lysozyme but negative for TRACP. The variable staining for TRACP in epithelia and kidney tubules was probably due to endogenous biotin.
Cardiovascular System
Rare interstitial MΦ in normal heart and artery, which were positive for CD68, were sometimes positive for TRACP with mab220 but not mab9C5. In 2 cases of atherosclerosis (1 carotid artery and 1 aorta), the foamy MΦ associated with atheroma were positive for TRACP with both mab220 and mab9C5.
Respiratory System
Alveolar MΦ of lung were always intensely positive for all 4 markers of MΦ. Reactive MΦ, epithelioid cells, and giant cells in lung tissue samples with granulomatous reactions, emphysema, or cancer were intensely positive as well.
Endocrine System
Interstitial and intercolloidal MΦ in normal thyroid were consistently positive for CD68 and were sometimes positive for TRACP, more so with mab220 than with mab9C5. In benign and neoplastic thyroid tumors and in goiter, increased numbers of MΦ were evident with stronger expression of TRACP with both mab220 and mab9C5. Sometimes, the thyroid epithelia were nonspecifically positive for TRACP staining using the LSAB2 detection system and dilute ascites but negative using purified IgGs and the biotin-free EnVision system.
Central Nervous System
Rare MΦ were detected when 3 neural tumors were stained with anti-CD68; TRACP expression was detected in 1 of the 3 cases. Abundant CD68+ MΦ were seen in 1 primary central nervous system large B-cell lymphoma. The MΦ were strongly positive when stained with mab220 but were negative with mab9C5.
Miscellaneous Tissue Samples
The MΦ in soft tissues were sometimes positive for TRACP; immunoreactivity with mab220 was more evident than with mab9C5. In skin, epithelial cells of sebaceous glands were always immunoreactive for TRACP ❚Image 5❚; Elsewhere in the small bowel, some epithelial cells were stained strongly for a TRACP-like antigen with mab9C5 (B, ×40). These were identified as neuroendocrine cells because they were positive for chromogranin (C, ×40). These neuroendocrine cells were negative when stained for TRACP with mab220.
❚Image 5❚ Skin from a case of solar elastosis showing moderate tartrate-resistant acid phosphatase staining in the sebaceous glands (monoclonal antibody 220, ×10).
staining with mab220 was stronger than with mab9C5. Epithelial cells of eccrine ducts and some cells of hair root sheath were occasionally weakly stained with mab220.
Restaining with the EnVision system and purified IgGs confirmed that sebaceous glands and their connected hair root sheaths were TRACP+, whereas the eccrine glands were negative. Osteoclasts were always strongly positive for CD68 and TRACP ❚Image 6❚ but negative for lysozyme. Weak mab220 reactivity was seen in chondrocytes of 1 cartilage specimen. When pathologic processes were present, the number of MΦ increased, as did the intensity of TRACP expression. For example, MΦ and giant cells associated with cysts, foreign body reactions, invasive high-grade tumors ❚Image 7A❚, and necrosis ❚Image 7B❚ were always strongly positive for TRACP expression. Mast cells were invariably positive for TRACP expression with both mab220 and mab9C5. In inflammatory tissues such as ileal Crohn disease ❚Image 8A❚ and sarcoidosis of lung ❚Image 8B❚, TRACP expression was intense in the abundant inflammatory MΦ and the giant cells and epithelioid cells in granulomas.
Neoplastic Tissue Samples
The tumor cells in 1 case of histiocytoma cutis were positive for TRACP expression with both mab220 and mab9C5; they were also positive for CD68. Tumor cells in a case of clear cell carcinoma of the ovary were positive for TRACP with mab9C5 but not mab220. All 7 cases of granular cell tumor were positive for CD68 expression but were negative for TRACP and lysozyme expression. All other tumor tissue samples, malignant and benign, were negative for all markers tested, including 4 cases of malignant fibrous histiocytoma, 2 cases of giant cell tumor of tendon sheath, and 1 other case of histiocytoma cutis. Benign tumors were often associated with fewer CD68+ MΦ. These MΦ were negative or weak for TRACP expression. However, mab220 consistently detected more MΦ than did mab9C5. Low-grade malignancies tended to be associated with fewer MΦ expressing less TRACP than the more abundant MΦ associated with high-grade tumors.
❚Image 6❚ Paget disease of bone showing strong tartrateresistant acid phosphatase (TRACP) expression by osteoclasts (monoclonal antibody [mab]220, ×10). The osteoclasts were also strongly positive when stained for TRACP with mab9C5 and for CD68. They were negative when stained for lysozyme.
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❚Image 7❚ Macrophages associated with a high-grade adenocarcinoma of prostate (A, monoclonal antibody [mab]220, ×4) and the palisading macrophages surrounding the necrotic center of a rheumatoid nodule (B, mab220, ×10) were strongly positive for tartrate-resistant acid phosphatase.
Discussion
The search for biomarkers of disease has intensified recently. Although increased serum TRACP activity has been known for many years to be associated with bone diseases, specific immunoassay of serum TRACP isoform 5b activity has only recently been realized as a sensitive and clinically relevant marker of osteoclast number and bone resorption. [6] [7] [8] [9] [10] [11] [15] [16] [17] [18] [19] [20] The most widely recognized application for immunoassay of serum TRACP-5b activity is in monitoring antiresorptive treatment in postmenopausal women. [8] [9] [10] [11] TRACP-5b activity can be elevated in these women in relation to collagen markers of resorption and declines in response to antiresorptive treatment. It may also be useful for characterization of bone metabolic abnormalities in patients with secondary hyperparathyroid bone disease 15 and patients with malignancies involving bone. 10, 16, 17, 20 In addition to TRACP-5b, serum contains TRACP isoform 5a, which is not related to osteoclast activity or bone resorption. 6 TRACP-5a constitutes the majority of circulating TRACP protein but has about 10-fold lower specific activity and a lower pH optimum than TRACP-5b. 5 Therefore, the serum TRACP5a protein level does not interfere significantly with the sensitivity or specificity of the TRACP-5b activity assay.
While investigating the usefulness of serum TRACP-5b as a marker for bone destruction and joint erosions in RA, Janckila et al 18, 19 found instead that serum TRACP protein (not activity) was increased in approximately 25% to 30% of patients with established disease. Subsequent experiments using an antibody specific for serum TRACP-5a (mab220) showed that the increased TRACP protein in RA serum samples was due to isoform 5a 14 and could be specifically secreted by MΦ and DCs in vitro. 19 The present study was undertaken to provide immunohistochemical evidence in human tissues that elevated serum TRACP-5a may be a marker for MΦ activation and inflammatory disease processes. CD68 and lysozyme were used in some cases as markers for monocyte-derived cells. TRACP expression was determined by using mab9C5 and mab220 antibodies. The mab9C5 reacts with an epitope in the C-terminal portion of the protein and reacts with all forms of TRACP. The mab220 reacts with the proteolytically sensitive "loop" peptide and reacts only with nascent proenzyme and mature TRACP-5a. Therefore, cells reactive with mab9C5 but not with mab220 would be considered to express only TRACP-5b. However, we would not be able to identify cells expressing only TRACP-5a because TRACP-5a reacts with mab9C5 and mab220.
Our first aim was to determine whether TRACP protein expression could delineate a subpopulation of inflammatory MΦ based on their association with certain pathologic processes. 1, 21, 22 This was validated based on the reaction pattern of CD68 and TRACP in several histopathologic contexts.
First, tissues affected by robust inflammation or granulomatous reactions contained large numbers of mononuclear and multinuclear cells with intense TRACP expression. These included foreign body reactions, sarcoidosis, and areas with necrotic centers such as cysts and rheumatoid nodules. TRACP expression was far less in tissues with acute inflammation or hyperplastic processes.
Second, in neoplastic tissues, the number of MΦ and their expression of TRACP were less within and around benign and low-grade malignant tumors. In contrast, high-grade invasive tumors with rapid cell turnover and necrosis were associated with larger numbers of TRACP-expressing mononuclear and multinuclear MΦ. Third, MΦ with strong TRACP expression were abundant in normal tissues exposed to high levels of foreign antigen exposure. Alveolar MΦ of lung and lamina propria MΦ of gastrointestinal tissue samples were prime examples of this.
Fourth, in hematopoietic tissue samples, CD68 expression was evident in virtually all MΦ, including those in normal bone marrow, red pulp of normal spleen, and the tingible body MΦ in the germinal centers of lymph node, spleen, and tonsil. However, TRACP was not detectable in normal bone marrow or red pulp MΦ with mab9C5, and only a few CD68+ cells stained with mab220. Similarly, tingible body MΦ stained occasionally and weakly with anti-TRACP antibodies. Red pulp MΦ and tingible body MΦ are normally responsible for clearing senescent and apoptotic cells, ie, noninflammatory processes. In the same tissue samples, some MΦ associated with splenic white pulp and small lipid granulomas in spleen and lymph node samples were strongly positive for TRACP expression. Also, sinus histiocytes in lymph nodes were weakly or moderately positive for TRACP, whereas some germinal center MΦ of the same tissues were intensely positive.
A role for TRACP in microbicidal activity and antigen processing by MΦ and DCs has been proposed based on experimental evidence from mouse models of normal TRACP expression, 3,23 targeted mutation, 24 and overexpression. 25 Our results derived from human tissue samples are consistent with and support this hypothesis.
Our second aim was to determine whether mab220 was more sensitive or specific than mab9C5 for inflammatory MΦ. The mab220 reacts with the loop peptide of intact TRACP protein; the epitope is destroyed by trypsin proteolysis in vitro and is absent from natural TRACP-5b. 12 Therefore, immunohistochemical reactivity with mab220 reveals the presence of precursor TRACP protein and mature TRACP-5a. Furthermore, the 220 epitope is accessible to specific antibody binding in the native and denatured states. As such, it is an excellent target for immunohistochemical staining but still requires heat-induced epitope retrieval for maximum sensitivity. Any cell expressing TRACP should be reactive with mab220, although the portion of the TRACP protein that is processed to isoform 5b will not be reactive with mab220. The mab9C5 reacts with an epitope present in the C-terminal half of the protein. It does not react with the native TRACP protein but does so with all forms of TRACP only after denaturation. 26 For maximum sensitivity in immunohistochemical studies, formalin-fixed tissue sections must be treated with heat-induced epitope retrieval.
In general, mab220 gave stronger reactions than mab9C5, even in our follow-up studies using balanced amounts of purified IgGs in the LSAB2 or EnVision system. This would seem to suggest that the amount of unprocessed precursor and isoform 5a detected by mab220 are in greater abundance than the total amount of TRACP protein as detected by mab9C5. More likely, it reflects the different immunoreactivities of these 2 antibodies. This could be due to a number of factors, including differences in epitope accessibility, extent and mechanisms of epitope recovery by heat, 27-29 and intrinsic affinity of the antibodies. The multiplicity of potential factors involved in immunohistochemical studies makes it difficult to speculate on the relative abundance of TRACP isoforms present in the cells.
We saw mab9C5 staining in the absence of mab220 staining in only 1 case. A minority of cells within the gut epithelia, especially stomach and small bowel, were strongly immunoreactive with mab9C5 but negative when stained with mab220. These cells were identified as neuroendocrine cells based on chromogranin expression (Image 4C). Because mab220 did not react with these cells, they probably express a protein that cross-reacts with TRACP by a common mab9C5 epitope.
There were many cases in which both TRACP antibodies gave a negative result in CD68+ MΦ. If cells were not stained by mab220, we concluded they were not expressing TRACP to a significant degree and could not be a source of serum TRACP-5a. On the other hand, cells staining strongly for mab220 may indeed be the source of serum TRACP-5a, even though they may also express TRACP-5b. It previously was shown that MΦ and DCs expressing strong TRACP in vitro selectively secrete isoform 5a but retain isoform 5b intracellularly. In contrast, osteoclasts secrete high levels of isoform 5b and some isoform 5a. 12, 19 The presence of TRACP in cells other than those of monocyte origin should be addressed. Other investigators have demonstrated TRACP in a variety of mouse and rat organs using histochemical studies, immunohistochemical studies, Western blot, Northern blot, reverse transcriptase-polymerase chain reaction (RT-PCR), and in situ hybridization. 3, 24, [30] [31] [32] Tissue MΦ and DCs could be the source of TRACP messenger RNA and protein in whole or partially purified tissue homogenates used for Western blot, Northern blot, and RT-PCR. Histochemical, immunohistochemical, and in situ hybridization demonstration of TRACP activity, protein, and messenger RNA, respectively, in specific cells would be more convincing evidence for TRACP expression outside the MΦ system. Our results with immunohistochemical studies in human tissue samples in the present and previous studies 2 are in general agreement with studies conducted in rodents showing that strong TRACP expression is primarily in osteoclasts and other MΦ-derived cells in diverse tissues.
TRACP was also demonstrated in normal and neoplastic MZ lymphocytes of spleen, which also expressed surface CD21. MZ cells were previously shown to express TRACP using immunohistochemical staining techniques in rat 32 and human tissue samples. 33 MZ lymphocytes are not of MΦ lineage, but owing to their unique location and ability to capture bloodborne immune complexes, they are considered important in innate resistance. 34 The secretory epithelial cells of sebaceous glands expressed TRACP, which may be another clue to the possible role of TRACP in innate resistance. We were unable to demonstrate TRACP in human brain as described in rat by Lång et al. 31 However, we did not survey the entire central nervous system, only cerebral tissue resected from three patients with gliomas. It may be noteworthy that neuroendocrine cells in gastrointestinal mucosa stained strongly with anti-TRACP mab9C5 but were negative with anti-TRACP mab220. The true identity of the mab9C5-reactive substance in these cells is unknown. The sporadic and patchy staining for TRACP in renal tubules and epithelial cells of the gastrointestinal and genitourinary tracts was attributed primarily to endogenous biotin.
One may ask why the serum TRACP-5b activity assay is so specific for diseases of increased bone resorption and is not elevated in a host of other pathologic states involving inflammation. At the same time, TRACP-5a activity and protein are not increased or responsive to antiresorptive therapy in postmenopausal women. Nascent intact TRACP is proteolytically processed into isoform 5b by cysteine proteases, resulting in activation of phosphatase 35 and increased reactive oxygen species generating capacity. 36, 37 We hypothesize that MΦ retain this processed TRACP-5b in the endosomal-lysosomal compartment for intracellular degradation purposes, whereas intact TRACP-5a is alternatively glycosylated with N-acetyl neuraminic acid and is secreted for some unknown extracellular function. 12 With this model, in diseases with a strong inflammatory component and expansion of activated MΦ, such as RA, the serum TRACP-5a protein level becomes elevated, whereas the serum TRACP-5b level remains normal. Alternatively, under conditions of intense inflammation, strong expression of TRACP and other lysosomal components may saturate the lysosomal compartments. Excess TRACP may then be shunted with other lysosomal enzymes to the constitutive secretory pathway upon which it is differentially glycosylated and obtains sialic acid. 38 Osteoclasts, on the other hand, actively secrete TRACP5b as a lysosomal-endosomal product. Ljusberg et al 35 constructed a model proposing that osteoclastic TRACP is secreted through the ruffled border into the acidic resorption lacuna with cathepsin K, where it is processed into isoform 5b, which then dephosphorylates osteopontin with high specific activity. 39 It is then released to the circulation during osteoclast migration. Halleen et al 40, 41 instead proposed that osteoclastic TRACP is proteolyzed into isoform 5b within the intracellular endosomal compartment upon which it assists in degradation of endocytosed bone matrix products by reactive oxygen species generation. It is then released with bone matrix fragments through the functional secretory domain as a "waste" product to be rapidly degraded in the circulation. In either case during increased osteoclastic activity and bone resorption, TRACP-5b activity becomes elevated in the circulation whereas TRACP-5a does not. The strong reactivity of mab220 with osteoclasts in this and previous studies 12 may simply reflect the abundance of precursor TRACP needed to continuously generate isoform 5b for ongoing enzymatic and oxidative processes.
We have confirmed and extended our previous findings of TRACP expression in monocyte-derived cells. Furthermore, our findings indicate that TRACP expression is highly restricted to activated or inflammatory MΦ and their derivatives, including osteoclasts. The mab220 is more sensitive than mab9C5 for demonstration of TRACP in formalin-fixed, paraffin-embedded tissue samples, perhaps because of the different nature of the cognate epitopes or antibody affinity rather than preferential expression of intact TRACP or TRACP-5a. Nevertheless, because of the demonstrated restricted expression of TRACP, including isoform 5a, in a large variety of normal and diseased tissue samples, elevated serum TRACP-5a in RA is most probably derived from increased numbers of inflammatory MΦ and not from osteoclasts or other non-MΦ-derived cells. Serum TRACP-5a may become a useful specific MΦ marker in other chronic inflammatory diseases.
